Read more

April 06, 2022
1 min read
Save

Top in endocrinology: Insulin price cap, 2 mg semaglutide for type 2 diabetes

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The U.S. House of Representatives recently passed the Affordable Insulin Now Act, which aims to cap insulin prices at $35 per month. If approved by the Senate, the bill would go into effect January 2023.

A review of the insulin price cap bill was the top story in endocrinology last week.

insulin shot
Source: Adobe Stock

Another top story was about the FDA’s approval of a weekly injection of 2 mg semaglutide to lower HbA1c and improve glycemic control in adults with type 2 diabetes whose target was not met with 0.5 mg and 1 mg doses.

Read these and more top stories in endocrinology below:

US House passes bill to cap insulin cost at $35 per month

A bill to cap the cost of insulin prices at $35 per month for Americans with diabetes was approved by the U.S. House of Representatives. Read more.

FDA approves 2 mg semaglutide to lower HbA1c in type 2 diabetes

The FDA has approved a once-weekly 2 mg semaglutide injection in conjunction with diet and exercise to lower HbA1c and reduce the risk for cardiovascular events for adults with type 2 diabetes, according to a press release. Read more.

FDA grants final approval to oral testosterone undecanoate for men with hypogonadism

The FDA has given final approval for an oral testosterone undecanoate therapy for men with a deficiency or absence of endogenous testosterone or hypogonadism, according to an industry press release. Read more.

Shift work linked to delayed onset of menopause

Women who were employed in rotating or night shift work at some point in their lives are more likely to experience delayed onset of menopause compared with women working only during the day, according to study data published in Menopause. Read more.

Risk for osteonecrosis of the jaw higher with denosumab vs. bisphosphonates

Adults with osteoporosis have a higher risk for developing osteonecrosis of the jaw with denosumab therapy compared with bisphosphonates, according to study findings published in the Journal of Bone and Mineral Research. Read more.